摘要
探讨针对激素受体阳性/人类表皮生长因子受体2阴性(HR+/HER2-)绝经后晚期乳腺癌患者应用阿贝西利联合非甾体类芳香化酶抑制剂一线治疗的效果。以玉林市红十字会医院在2022年1月—2023年4月收治的92例HR+/HER2-绝经后晚期乳腺癌患者为研究对象,采用随机数字表法将其分为对照组(n=46,应用非甾体类芳香化酶抑制剂一线治疗)和研究组(n=46,在对照组基础上应用阿贝西利治疗),对比两组疗效、不良反应发生率、生活质量。研究发现,针对HR+/HER2-绝经后晚期乳腺癌患者应用阿贝西利联合非甾体类芳香化酶抑制剂一线治疗,疗效有所提高,不良反应未增加,安全性较高,患者生活质量显著提高,值得推广。
To investigate the effect of first-line treatment with abeciclib combined with non-steroidal aromatase inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-)postmenopausal advanced breast cancer.A total of 92 patients with HR+/HER2-postmenopausal advanced breast cancer admitted to Yulin Red Cross Hospital from January 2022 to April 2023 were divided into control group(n=46,first-line treatment with non-steroidal aromatase inhibitors)and study group(n=46,treatment with abeciclib on the basis of control group)by random number table method,and the efficacy,incidence of adverse reactions,and quality of life were compared between the two groups.The study found that the first-line treatment of HR+/HER2-postmenopausal advanced breast cancer patients with abeciclib combined with non-steroidal aromatase inhibitors has improved the efficacy,no increase in adverse reactions,high safety,and significantly improved the quality of life of patients,which is worthy of promotion.
作者
陈燕红
王玮
刘玉娟
覃清清
黄江昌
Chen Yanhong;Wang Wei;Liu Yujuan;Qin Qingqing;Huang Jiangchang(Yulin Red Cross Hospital,Yulin 537000;Guangxi Medical University,Nanning,Guangxi 530021)
出处
《科技与健康》
2024年第15期113-116,共4页
Technology and Health
关键词
激素受体阳性
晚期乳腺癌
阿贝西利
人类表皮生长因子受体2阴性
hormone receptor positive
advanced breast cancer
Abeciclib
Human epidermal growth factor receptor 2 negative
